Bo L Hønge1,2, Mikkel S Petersen2, Sanne Jespersen1,3, Candida Medina4, David D S Té4, Bertram Kjerulff2, Mads M Jensen1,2, Ditte Steiniche1,3, Joakim Esbjörnsson5,6, Alex L Laursen3, Christian Wejse1,3,7, Henrik Krarup8, Bjarne K Møller2, Christian Erikstrup2. 1. Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau. 2. Department of Clinical Immunology. 3. Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark. 4. National HIV Programme, Ministry of Health, Bissau, Guinea-Bissau. 5. Department of Laboratory Medicine, Lund University, Lund, Sweden. 6. Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom. 7. GloHAU, Center for Global Health, School of Public Health, Aarhus University, Aarhus. 8. Section of Molecular Diagnostics, Clinical Biochemistry, Aalborg University Hospital, Denmark.
Abstract
BACKGROUND: HIV-2 may slow progression of a subsequently acquired HIV-1 infection through cross-neutralizing antibodies and polyfunctional CD8 T cells. We hypothesized that HIV-1/2 dually infected patients compared with HIV-1-infected patients had more preserved immune maturation subsets and less immune activation of T and B cells. METHODS: ART-naive patients with HIV-1 (n = 83) or HIV-1/2 dual (n = 27) infections were included in this cross-sectional study at an HIV clinic in Guinea-Bissau. Peripheral blood mononuclear cells (PBMCs) were analyzed by flow cytometry according to T-cell maturation and activation, regulatory T-cell fraction, and B-cell maturation and activation. RESULTS: HIV-1/2 dually infected patients had lower levels of HIV-1 RNA compared with patients with HIV-1 infection, but the levels of total HIV RNA (HIV-1 and HIV-2) were similar in the two patient groups. T-cell maturation, and proportions of regulatory T cells (FoxP3+) were also similar in the two groups. HIV-1/2 dually infected patients had higher proportions of CD4 and CD8 T cells positive for the activation marker CD38, but there was no difference in other T-cell activation markers (CD28, CTLA-4, PD-1). HIV-1/2 dually infected patients also had higher proportions of IgM-only B cells and plasmablasts. CONCLUSION: HIV-1/2 was not associated with less immune perturbations than for HIV-1 infection.
BACKGROUND:HIV-2 may slow progression of a subsequently acquired HIV-1 infection through cross-neutralizing antibodies and polyfunctional CD8 T cells. We hypothesized that HIV-1/2 dually infectedpatients compared with HIV-1-infectedpatients had more preserved immune maturation subsets and less immune activation of T and B cells. METHODS: ART-naive patients with HIV-1 (n = 83) or HIV-1/2 dual (n = 27) infections were included in this cross-sectional study at an HIV clinic in Guinea-Bissau. Peripheral blood mononuclear cells (PBMCs) were analyzed by flow cytometry according to T-cell maturation and activation, regulatory T-cell fraction, and B-cell maturation and activation. RESULTS:HIV-1/2 dually infectedpatients had lower levels of HIV-1 RNA compared with patients with HIV-1 infection, but the levels of total HIV RNA (HIV-1 and HIV-2) were similar in the two patient groups. T-cell maturation, and proportions of regulatory T cells (FoxP3+) were also similar in the two groups. HIV-1/2 dually infectedpatients had higher proportions of CD4 and CD8 T cells positive for the activation marker CD38, but there was no difference in other T-cell activation markers (CD28, CTLA-4, PD-1). HIV-1/2 dually infectedpatients also had higher proportions of IgM-only B cells and plasmablasts. CONCLUSION:HIV-1/2 was not associated with less immune perturbations than for HIV-1 infection.
Authors: Joakim Esbjörnsson; Marianne Jansson; Sanne Jespersen; Fredrik Månsson; Bo L Hønge; Jacob Lindman; Candida Medina; Zacarias J da Silva; Hans Norrgren; Patrik Medstrand; Sarah L Rowland-Jones; Christian Wejse Journal: AIDS Res Ther Date: 2019-09-05 Impact factor: 2.250
Authors: Sivasankaran Munusamy Ponnan; K K Vidyavijayan; Kannan Thiruvengadam; Nancy Hilda J; Manikannan Mathayan; Kailapuri Gangatharan Murugavel; Luke Elizabeth Hanna Journal: Front Immunol Date: 2021-04-16 Impact factor: 7.561